Search research articles
Contact Us
Filters
Showing results (1-10 of 13) with videos related to
Page
of 2
Sort By:
JTO Clinical and Research Reports
|
March 29, 2024
Cabozantinib Response in a Patient With NSCLC Harboring Both MET Exon 14 Skipping Mutation and Secondary RET Fusion: A Case Report
Carlos Torrado, Jamie Feng, Elizabeth Faour, et al.
Histopathology
|
July 2, 2026
TROP2 immunoreactivity in pulmonary large cell neuroendocrine carcinoma
Michael Minkley, Kashif Ravasia, Thi Nghiem, et al.
Virchows Archiv : an International Journal of Pathology
|
February 16, 2026
Utility of RB1 immunohistochemistry for prognostic subtyping of pulmonary large cell neuroendocrine carcinoma
Michael Minkley, Kashif Ravasia, Thi Nghiem, et al.
Current Oncology (Toronto, Ont.)
|
August 25, 2023
Beyond PACIFIC: Real-World Outcomes of Adjuvant Durvalumab According to Treatment Received and PD-L1 Expression
Marie-Hélène Denault, Jamie Feng, Shelley Kuang, et al.
Lung Cancer (Amsterdam, Netherlands)
|
May 15, 2025
Prognostic and predictive effects of TP53 co-mutation in patients with non-small cell lung cancer with rare treatable driver mutations
Jamie Feng, Katrina Hueniken, Zhen Jason Fan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 7, 2026
Retreatment with First-Generation Selective RET Inhibitors in RET-Rearranged NSCLC Pretreated with Selpercatinib or Pralsetinib - Results from the RET-MAP Registry
Arianna Marinello, Julia K Rotow, Meghanne Lomibao, et al.
Therapeutic Advances in Medical Oncology
|
December 30, 2024
Analysis of outcomes in resected early-stage NSCLC with rare targetable driver mutations
Nadia Ghazali, Jamie Feng, Katrina Hueniken, et al.
JTCVS Open
|
May 4, 2026
Preoperative circulating tumor DNA detection and occult lymph node metastases in clinical stage I lung cancer: The lung DETECT study
Zachary Coyne, Jamie Feng, Sameena Khan, et al.
JAMA Network Open
|
July 25, 2023
Association of Circulating Tumor DNA Testing Before Tissue Diagnosis With Time to Treatment Among Patients With Suspected Advanced Lung Cancer: The ACCELERATE Nonrandomized Clinical Trial
Miguel García-Pardo, Kasia Czarnecka-Kujawa, Jennifer H Law, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
February 23, 2026
Identifying patients with high risk stage I NSCLC using tumor-informed plasma ctDNA
Jamie Feng, Sameena Khan, Thomas Waddell, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 13) with videos related to
Sort By:
Page
of 2
JTO Clinical and Research Reports
|
March 29, 2024
Cabozantinib Response in a Patient With NSCLC Harboring Both MET Exon 14 Skipping Mutation and Secondary RET Fusion: A Case Report
Carlos Torrado, Jamie Feng, Elizabeth Faour, et al.
Histopathology
|
July 2, 2026
TROP2 immunoreactivity in pulmonary large cell neuroendocrine carcinoma
Michael Minkley, Kashif Ravasia, Thi Nghiem, et al.
Virchows Archiv : an International Journal of Pathology
|
February 16, 2026
Utility of RB1 immunohistochemistry for prognostic subtyping of pulmonary large cell neuroendocrine carcinoma
Michael Minkley, Kashif Ravasia, Thi Nghiem, et al.
Current Oncology (Toronto, Ont.)
|
August 25, 2023
Beyond PACIFIC: Real-World Outcomes of Adjuvant Durvalumab According to Treatment Received and PD-L1 Expression
Marie-Hélène Denault, Jamie Feng, Shelley Kuang, et al.
Lung Cancer (Amsterdam, Netherlands)
|
May 15, 2025
Prognostic and predictive effects of TP53 co-mutation in patients with non-small cell lung cancer with rare treatable driver mutations
Jamie Feng, Katrina Hueniken, Zhen Jason Fan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 7, 2026
Retreatment with First-Generation Selective RET Inhibitors in RET-Rearranged NSCLC Pretreated with Selpercatinib or Pralsetinib - Results from the RET-MAP Registry
Arianna Marinello, Julia K Rotow, Meghanne Lomibao, et al.
Therapeutic Advances in Medical Oncology
|
December 30, 2024
Analysis of outcomes in resected early-stage NSCLC with rare targetable driver mutations
Nadia Ghazali, Jamie Feng, Katrina Hueniken, et al.
JTCVS Open
|
May 4, 2026
Preoperative circulating tumor DNA detection and occult lymph node metastases in clinical stage I lung cancer: The lung DETECT study
Zachary Coyne, Jamie Feng, Sameena Khan, et al.
JAMA Network Open
|
July 25, 2023
Association of Circulating Tumor DNA Testing Before Tissue Diagnosis With Time to Treatment Among Patients With Suspected Advanced Lung Cancer: The ACCELERATE Nonrandomized Clinical Trial
Miguel García-Pardo, Kasia Czarnecka-Kujawa, Jennifer H Law, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
February 23, 2026
Identifying patients with high risk stage I NSCLC using tumor-informed plasma ctDNA
Jamie Feng, Sameena Khan, Thomas Waddell, et al.
Page
of 2